Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib vs Teriflunomide in Relapsing Multiple Sclerosis
NCT05156281Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2021
- Primary completion
- Jul 2026
- Countries
- 27
01
Overview
A Phase 3 trial of remibrutinib in multiple sclerosis (MS), sponsored by Novartis. Started Dec 2021; status: active, not recruiting.
02
Drugs
remibrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05156281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05156281.